Ropca A/S

ROPCA develops, produces, and markets an AI and robotics-based automation platform for ultrasound examinations. Our initial market focus is Rheumatology, where our products offer a solution that relieves clinical workload, reduces costs, and ensures faster and more consistent diagnostics—without requiring a specialist to be present.

Financial PerformanceThe income statement for 2025 records a net loss of DKK 5,159,653, compared to a loss of DKK 2,313,445 in the prior year. The balance sheet as at 31 December 2025 reflects total equity of DKK 13,580,552. To support continued development and commercialisation activities, the Company completed a capital increase of DKK 4,756,385 during the year, strengthening the equity base and providing additional working capital for ongoing operations.

Commercial and Clinical Progress…

Financial PerformanceThe income statement for 2025 records a net loss of DKK 5,159,653, compared to a loss of DKK 2,313,445 in the prior year. The balance sheet as at 31 December 2025 reflects total equity of DKK 13,580,552. To support continued development and commercialisation activities, the Company completed a capital increase of DKK 4,756,385 during the year, strengthening the equity base and providing additional working capital for ongoing operations.Commercial and Clinical Progress2025 represented another year of meaningful advancement for ROPCA across both commercial and clinical dimensions. The Company completed five new ARTHUR installations during the year, further expanding its installed base across Denmark, Germany, Austria, Switzerland, and the United States, where ARTHUR is …

Subsequent to the balance sheet date, the Company filed its FDA submission in January 2026 and completed a further capital increase of DKK 5.1 million in February 2026.

No other events materially affecting the Company's financial position have occurred subsequent to the financial year-end.

Other contingent liabilities

The company has no contingent liabilities as of December 31, 2025.

The Company has not provided any security or other collateral in assets at 31 December 2025.